On October 30, 2026, a clinical trial update was recorded for a study involving liraglutide, an approved compound. The trial is titled "A Study on the Safety and Clinical Efficacy of Guominkang in the Treatment of Diabetic Kidney Disease." It is registered under identifier NCT07907965. The study is listed as Phase 2. Its current status is active but not recruiting, meaning enrollment has closed while the trial continues. No results have been posted for this study as of the update date. The trial record does not specify findings, outcomes, or efficacy data at this stage. This brief reports only the status and classification as listed in the trial registry. Readers interested in tracking the progress of this study can refer to the official registry entry for further updates on enrollment status and eventual results. For additional context on liraglutide, including its approved uses and regulatory history, readers can consult the compound overview.
Liraglutide Trial Update: Phase 2 Diabetic Kidney Disease Study Active
See the full liraglutide overview
Source: https://clinicaltrials.gov/study/NCT07907965